A carregar...

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis

BACKGROUND. In the U.S., the addition of bevacizumab to first‐line chemotherapy in metastatic colorectal cancer (mCRC) has been demonstrated to provide 0.10 quality‐adjusted life years (QALYs) at an incremental cost‐effectiveness ratio (ICER) of $571,000/QALY. Due to variability in pricing, value fo...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Goldstein, Daniel A., Chen, Qiushi, Ayer, Turgay, Chan, Kelvin K. W., Virik, Kiran, Hammerman, Ariel, Brenner, Baruch, Flowers, Christopher R., Hall, Peter S.
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5469597/
https://ncbi.nlm.nih.gov/pubmed/28592621
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0455
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!